LTRN
Lantern Pharma Inc.
There isn't enough reported data to score LTRN yet.
LTRN Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
LTRN's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
LTRN PE Valuation
LTRN has no meaningful PE right now: it lost money over the past year.
LTRN Forward outlook
There aren't enough analyst estimates for LTRN to show an outlook.
LTRN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$1.62 | +$0.16 |
| Q1 2026 | -$1.45 | +$0.39 |
| Q4 2025 | -$1.57 | +$0.36 |
| Q3 2025 | -$1.75 | +$0.02 |
| Q2 2025 | -$1.78 | -$0.14 |
| Q1 2025 | -$1.84 | -$0.22 |
| Q4 2024 | -$1.93 | -$0.46 |
| Q3 2024 | -$1.77 | -$0.37 |
LTRN is still losing money, but less than at its worst: $1.62 per share over the past year, against $1.93 at its worst in late 2024.
LTRN Quarterly Revenue
LTRN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2025 | -$2.8M | +$1.2M |
| Q3 2025 | -$4.6M | +$1M |
| Q2 2025 | -$3.9M | +$1.3M |
| Q1 2025 | -$4.4M | -$1.3M |
| Q4 2024 | -$4M | -$584.4K |
| Q3 2024 | -$5.6M | -$2M |
| Q2 2024 | -$5.2M | -$1.6M |
| Q1 2024 | -$3.1M | +$695.3K |
LTRN has burned cash in almost every quarter: −$16M over the past year, against −$18M the year before.
LTRN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +10% | +1.2M shares |
| 1 year | +15% | +1.6M shares |
| 3 years | +14% | +1.6M shares |
| 5 years | +11% | +1.2M shares |
| Available history | +100% | +6.2M shares |
LTRN has 12M diluted shares, up 15% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2022 | — |
| Q3 2022 | — |
| Q1 2020 | — |
| Q4 2019 | — |
| Q3 2019 | — |
LTRN Net Leverage
LTRN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LTRN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 23.8 | Oversold |
| Stochastic | 2.1 | Oversold |
LTRN's weekly RSI is 24 (oversold) and its Stochastic is 2 (oversold).
LTRN PE vs Healthcare Sector
LTRN has no meaningful PE right now: it lost money over the past year.
LTRN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.74 | 38% below |
| 20 week MA | $1.84 | 75% below |
| 50 week MA | $2.49 | 82% below |
| 100 week MA | $3.18 | 86% below |
| 200 week MA | $3.94 | 88% below |
LTRN is in a downtrend: it's below all five of its weekly moving averages, and 88% below its 200-week average.
LTRN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $14.8 | $19.2 | +30% |
| 2021 | $19.2 | $7.31 | -62% |
| 2022 | $7.31 | $5.62 | -23% |
| 2023 | $5.62 | $4.28 | -24% |
| 2024 | $4.28 | $3.42 | -20% |
| 2025 | $3.42 | $3.48 | +1.8% |
| 2026 YTD | $3.48 | $0.46 | -87% |
LTRN has finished lower in four of the last six years. It's down 87% so far in 2026.